Recro Pharma Competitors

Theratechnologies (NASDAQ:THTX) and Recro Pharma (NASDAQ:REPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are held by institutional investors. Comparatively, 56.3% of Recro Pharma shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Theratechnologies has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Recro Pharma has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theratechnologies and Recro Pharma, as reported by MarketBeat.

Theratechnologies currently has a consensus price target of $7.1250, suggesting a potential upside of 97.92%. Recro Pharma has a consensus price target of $12.00, suggesting a potential upside of 334.78%. Given Recro Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Recro Pharma is more favorable than Theratechnologies.

Profitability

This table compares Theratechnologies and Recro Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Theratechnologies and Recro Pharma's revenue, earnings per share and valuation.

Theratechnologies has higher earnings, but lower revenue than Recro Pharma. Theratechnologies is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats Theratechnologies on 10 of the 14 factors compared between the two stocks.

RedHill Biopharma (NASDAQ:RDHL) and Recro Pharma (NASDAQ:REPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Risk & Volatility

RedHill Biopharma has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Recro Pharma has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for RedHill Biopharma and Recro Pharma, as provided by MarketBeat.

RedHill Biopharma currently has a consensus price target of $20.00, suggesting a potential upside of 181.69%. Recro Pharma has a consensus price target of $12.00, suggesting a potential upside of 334.78%. Given Recro Pharma's higher possible upside, analysts plainly believe Recro Pharma is more favorable than RedHill Biopharma.

Institutional and Insider Ownership

20.4% of RedHill Biopharma shares are held by institutional investors. Comparatively, 56.3% of Recro Pharma shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares RedHill Biopharma and Recro Pharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares RedHill Biopharma and Recro Pharma's top-line revenue, earnings per share and valuation.

Recro Pharma has higher revenue and earnings than RedHill Biopharma. RedHill Biopharma is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats RedHill Biopharma on 10 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Frequency Therapeutics (NASDAQ:FREQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Recro Pharma and Frequency Therapeutics, as reported by MarketBeat.

Recro Pharma presently has a consensus target price of $12.00, suggesting a potential upside of 334.78%. Frequency Therapeutics has a consensus target price of $37.00, suggesting a potential upside of 285.82%. Given Recro Pharma's higher probable upside, equities analysts clearly believe Recro Pharma is more favorable than Frequency Therapeutics.

Institutional & Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 57.5% of Frequency Therapeutics shares are held by institutional investors. 23.1% of Recro Pharma shares are held by insiders. Comparatively, 15.4% of Frequency Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Recro Pharma and Frequency Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Recro Pharma has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Frequency Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Earnings & Valuation

This table compares Recro Pharma and Frequency Therapeutics' revenue, earnings per share and valuation.

Recro Pharma has higher revenue and earnings than Frequency Therapeutics. Frequency Therapeutics is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats Frequency Therapeutics on 9 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Recro Pharma and Hookipa Pharma's revenue, earnings per share and valuation.

Recro Pharma has higher revenue and earnings than Hookipa Pharma. Hookipa Pharma is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Recro Pharma and Hookipa Pharma, as reported by MarketBeat.

Recro Pharma currently has a consensus target price of $12.00, indicating a potential upside of 334.78%. Hookipa Pharma has a consensus target price of $21.1429, indicating a potential upside of 68.60%. Given Recro Pharma's higher probable upside, equities research analysts plainly believe Recro Pharma is more favorable than Hookipa Pharma.

Profitability

This table compares Recro Pharma and Hookipa Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

56.3% of Recro Pharma shares are owned by institutional investors. Comparatively, 33.4% of Hookipa Pharma shares are owned by institutional investors. 23.1% of Recro Pharma shares are owned by company insiders. Comparatively, 4.0% of Hookipa Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Recro Pharma has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Summary

Recro Pharma beats Hookipa Pharma on 11 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 34.0% of Verrica Pharmaceuticals shares are held by institutional investors. 23.1% of Recro Pharma shares are held by insiders. Comparatively, 40.2% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Recro Pharma and Verrica Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Recro Pharma and Verrica Pharmaceuticals, as reported by MarketBeat.

Recro Pharma currently has a consensus target price of $12.00, suggesting a potential upside of 334.78%. Verrica Pharmaceuticals has a consensus target price of $17.75, suggesting a potential upside of 39.87%. Given Recro Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Recro Pharma is more favorable than Verrica Pharmaceuticals.

Volatility & Risk

Recro Pharma has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500.

Earnings & Valuation

This table compares Recro Pharma and Verrica Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Recro Pharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats Verrica Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 10.8% of Oncternal Therapeutics shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Comparatively, 10.9% of Oncternal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Recro Pharma and Oncternal Therapeutics' top-line revenue, earnings per share and valuation.

Recro Pharma has higher revenue and earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Recro Pharma has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares Recro Pharma and Oncternal Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Recro Pharma and Oncternal Therapeutics, as reported by MarketBeat.

Recro Pharma presently has a consensus target price of $12.00, suggesting a potential upside of 334.78%. Oncternal Therapeutics has a consensus target price of $15.20, suggesting a potential upside of 134.57%. Given Recro Pharma's higher possible upside, analysts plainly believe Recro Pharma is more favorable than Oncternal Therapeutics.

Summary

Recro Pharma beats Oncternal Therapeutics on 10 of the 13 factors compared between the two stocks.